Navigation Links
Aratana Therapeutics Inc. to Report Third Quarter 2013 Financial Results
Date:11/5/2013

ientific personnel; our complete reliance on third-party manufacturers and third parties to conduct all our target animal studies and certain other development efforts; our lack of a sales organization; our significant costs of operating as a public company; our lack of effective internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our customers; impacts of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; our failure to comply with regulatory requirements; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an "emerging growth company," as defined in the JOBS Act; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in our charter documents and under Delaware law; and our intention not to pay dividends.  These and other important factors discussed under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, eve
'/>"/>
SOURCE Aratana Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Aratana Therapeutics Completes $15 Million Series B Financing
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
4. Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
5. Aratana Therapeutics Adds To Drug Development Team
6. Aratana Therapeutics Announces Full Exercise of Over-Allotment Option
7. Aratana Therapeutics to Report Second Quarter 2013 Financial Results
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Nile Therapeutics Reports 2011 Third Quarter Financial Results
10. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
11. Fate Therapeutics Strengthens Its iPSC Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- , The first grants awarded to ... (ESPE) Meeting  Investment supports innovative projects for ... field of growth  , EMD Serono, a ... , today announced the first recipients of the Grant ... announced during a Satellite Symposium organized by EMD Serono ...
(Date:9/18/2014)... About POCT POCT, ... clinical laboratory. It helps in making fast clinical ... medication. POCT is gaining popularity due to the ... as diabetes, heart disease, and obesity. It is ... to minimize errors during the diagnosis of patients. ...
(Date:9/18/2014)... September 18, 2014 ... http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the addition ... Global Strategic Business Report" report ... ,This report analyzes the worldwide markets ... by the following Product Segments: Polymeric ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global N-acetylcysteine Industry Report 2014 2
... EU Citizens (6%) Have Liver Diseases, 5th Most Common Cause of ... ... Abuse Takes 13,000,Number With Fatty Liver Disease Stable or Growing; Viral Hepatitis Declines, ... world gathered today in this historic Italian,city to attend the opening sessions of ...
... one for analyzing tumors , Doctors treating individuals with ... oxygen in a tumor very useful, because low levels of oxygen ... new method to do this and to image the surrounding organs ... to image tumors in mice by Murali Krishna and colleagues, at ...
... the biggest-selling,biologics developed during the boom years in biotech ... have lost patent,protection in the U.S. in 2007 or ... This opens up a huge potential market for biosimilars, ... report by Kalorama,Information, Biogenerics: the World Market for Biosimilars., ...
Cached Biology Technology:Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 2Liver Diseases: A Huge European Health Burden, But Some Trends are Positive 3JCI table of contents: April 22, 2008 2JCI table of contents: April 22, 2008 3JCI table of contents: April 22, 2008 4JCI table of contents: April 22, 2008 5JCI table of contents: April 22, 2008 6JCI table of contents: April 22, 2008 7JCI table of contents: April 22, 2008 8JCI table of contents: April 22, 2008 9JCI table of contents: April 22, 2008 10JCI table of contents: April 22, 2008 11JCI table of contents: April 22, 2008 12Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles 2
(Date:9/18/2014)... to undertake jaunts into the countryside each year could come ... century, according to new research. , Climate change could postpone ... as summer temperatures linger later into the year, Princeton University ... . For instance, the paper birch a popular foliage ... could change color one to three weeks later by the ...
(Date:9/18/2014)... 18, 2014 -- Arizona turned its newborn screening program into ... short months, earning it the first-ever Newborn Screening Quality Award ... Dimes presented Will Humble, M.P.H., Arizona,s Department of Health Services ... Mr. Humble established a policy of full transparency for the ... blood samples to the lab for analysis, and set a ...
(Date:9/18/2014)... The tropical rabbitfish which have devastated algal forests in ... the entire Mediterranean basin if their distribution continues to ... The study, by an international team of researchers led ... Fiona Tomas of the Mediterranean Institute for Advanced Studies ... Ecology ., Members of the team surveyed more than ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... has landed a University of Central Florida scientist more ... could have profound benefits in the search for cures ... Annette Khaled is conducting research into what triggers the ... surrounding cells. If its secrets could be unlocked and ...
... Contaminated seaweeds in Sydney Harbour could be threatening the small ... revealing that the harbour,s seaweeds have the world,s highest levels ... of the offspring of small crustaceans that feed on a ... exposed to copper at levels found in some parts of ...
... early diagnosis of Alzheimers, Parkinsons and other diseases has ... Jersey Technology Council competition. Based at NJITs business ... , a start-up company, was named most likely to ... entrepreneurs and investors. NeuroTrax develops ...
Cached Biology News:'Death protein' research secures funding for UCF scientists 2Sydney harbors deadly diet for sea creatures 2NJIT start-up company NeuroTrax named best in show 2
...
... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
Mouse monoclonal [7A6] to NFAT2 ( Abpromise for all tested applications). entrezGeneID: 4772 SwissProtID: O95644...
... are designed for ultra-sensitive detection of ... PVDF membranes. Since all necessary reagents ... antibodies), the WesternBreeze Kits save you ... and getting your final results. Solutions ...
Biology Products: